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A B S T R A C T
Background
Gastro-oesophageal reflux (GOR) is an extremely common and usually self-limiting condition in infants. When treatment is required,
Cisapride, a pro-kinetic agent, has been commonly prescribed for the symptomatic management of GOR. There have been recent
reports of possibly serious adverse events, e.g. an increased QTc interval, cardiac arrhythmias, and death, associated with the use of
Cisapride.
Objectives
To determine the effectiveness of Cisapride for symptoms of GOR compared with placebo or any other non-surgical treatments.
Search strategy
Searcheswere conducted of theCochraneCentral TrialsRegister and the specialisedTrials register of theCochraneUpperGastrointestinal
and Pancreatic Diseases Group, MEDLINE and Embase up till April 2002. Reference lists of relevant review articles and identified
trials were scrutinised and forward citation searches were performed in the Science Citation Index on all trials identified. The searches
were re-run in August 2003, May 2004, June 2005 and June 2006 and no new trials were found.
Selection criteria
Randomised controlled trials that compared oral Cisapride therapy with placebo or with other non-surgical treatments for children
with a diagnosis of GOR were included. Only studies in which Cisapride was administered orally for a minimum of one week and
which documented at least one of the primary outcomes were included. We excluded trials in which the majority of participants were
aged less than 28 days.
Data collection and analysis
The primary outcomes were defined as a change in symptoms at the end of treatment, presence of adverse events, occurrence of
clinical complications, and weight gain. The secondary outcomes included physiological measures of GOR or histological evidence of
oesophagitis. We dichotomised symptoms into ’same or worse’ vs ’improved’ and calculated summary odds ratios. Continuous measures
of GOR (e.g. reflux index) were summarised as a weighted mean difference. All outcomes were analysed using a random effects method.
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Main results
Searches identified nine trials which met the inclusion criteria. Eight trials compared Cisapride with placebo, of which seven (236
participants) reported data on symptoms of gastro-oesophageal reflux, and one reported data on the QTc interval (49 patients). The
odds ratio for ’same or worse’ vs ’improved symptoms’ at the end of treatment of 0.34 (95%CI 0.10, 1.19) did not show a statistically
significant difference between the two interventions. There was significant heterogeneity between the studies and the funnel plot
suggested publication bias. In a sensitivity analysis, the definition of outcomes was changed to ’any symptoms’ vs ’no symptoms’. This
resulted in the exclusion of three trials (one of them the largest, best quality trial). The resulting pooled odds ratio showed a significant
effect of Cisapride (OR 0.19, 95%CI 0.08, 0.44). Five studies reported adverse events. Four reported adverse events (mainly diarrhoea)
but the difference was not statistically significant (OR 1.80, 95%CI 0.87, 3.70). One trial found no difference in the QTc after 3 to
8 weeks of treatment. Cisapride was associated with a statistically significant reduction in the reflux index (weighted mean difference
-6.49, 95%CI -10.13, -2.85), but as reflux index and clinical symptoms are poorly correlated, the clinical importance of this finding
is uncertain. Other measures of oesophageal pH monitoring did not reach significance. One included study compared Cisapride with
Gaviscon (or Gaviscon and Carobel). The odds ratio for ’same or worse’ vs ’improvement’ in the Cisapride group compared with
Gaviscon was 3.26 (95%CI 0.93-11.38).
Authors’ conclusions
We found no clear evidence that Cisapride reduces symptoms of GOR. The results suggested substantial publication bias favouring
studies showing a positive effect of Cisapride. This finding is supported by the report of one unpublished multi-centre study of 134
patients, which was reported to show no evidence of a significant effect of Cisapride. Due to reports of fatal cardiac arrhythmias or
sudden death, from July 2000, cisapride was restricted to a limited access programme supervised by a paediatric gastrologist in the USA
and in Europe, to patients treated within a clinical trial or safety study or registry programme.
P L A I N L A N G U A G E S U M M A R Y
Cisapride treatment for gastro-oesophageal reflux in children
We found no clear evidence that Cisapride reduces symptoms of Gastro-oesophageal reflux (GOR). Due to reports of fatal cardiac
arrhythmias or sudden death, from July 2000, cisapride was restricted to a limited access programme supervised by a paediatric
gastrologist in the USA and in Europe, to patients treated within a clinical trial or safety study or registry programme.
B A C K G R O U N D
Gastro-oesophageal reflux (GOR), or the passage of gastric con-
tents into the oesophagus, has a multifactorial pathophysiology.
Regurgitation of stomach contents into the oesophagus is nor-
mally prevented by the action of the lower oesophageal sphinc-
ter (LES). Two different mechanisms contribute to LES tone: the
skeletal muscle of the diaphragm which surrounds the oesopha-
gus as it passes through the diaphragm, and the smooth muscle at
the gastro-oesophageal junction. Low basal oesophageal sphinc-
ter pressure and transient relaxation of the LES, oesophageal dys-
motility resulting in impaired clearance, and delayed emptying of
the stomach and duodenum can all contribute to GOR.
In most infants with GOR the outcome is benign. The determin-
ing factor in seeking medical assistance may be parental anxiety
or intolerance of symptoms rather than the presence of significant
complications. In a small minority, GOR is associated with signifi-
cant problems such as respiratory sequelae (chronic cough, wheez-
ing, apnoea, hoarseness, stridor, recurrent bronchitis, pneumo-
nia), neuro-behavioural manifestations (back-arching, feeding re-
fusal, rumination, non-specific irritability, sleep disturbance), oe-
sophagitis, oesophageal strictures, and failure to thrive. The term
gastro-oesophageal reflux disease (GORD) describes the associa-
tion of definite pathology, in most cases oesophagitis, with reflux.
Infantile gastro-oesophageal reflux has a peak incidence around 4
months and resolves spontaneously by 1 to 2 years of age in most
patients (Rudolph 1996; Nelson 1997). A much smaller number
of children have symptoms of GOR later in childhood; only some
of these children will have had GOR in infancy. Less than 50% of
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children who develop reflux after the age of 3 have spontaneous
resolution of symptoms (Treem 1991). A substantial proportion
of these children will have other problems, including neurological
or chronic respiratory disease.
A diagnosis of GOR is usually made on clinical grounds. Treat-
ment for GOR, when this is deemed necessary, can be started
before performing expensive and often unnecessary investigations
(the Working Group of the European Society of Paediatric Gas-
tro-Enterology and Nutrition (ESPGAN) onGastro-Oesophageal
Reflux, in Vandenplas 1993). Though not always essential for di-
agnosis, there are a number of investigations available to assess
the cause and quantity of the reflux and to detect the presence of
reflux-related complications: extended (18-24 hour) oesophageal
pH monitoring, upper gastro-intestinal endoscopy, oesophageal
manometry, scintigraphy, or sonography. These have low sensi-
tivities and specificities and do not allow correlation of the reflux
episodes with the patient’s symptoms. Moreover, these investiga-
tions are generally poor predictors of how children will respond
to treatment (Cucchiara 1996). A few variables, e.g. sleep reflux,
acid clearing time, percentage time pH<4, oesophageal motility
parameters, may predict which children are likely to have continu-
ing problems despite medical treatment (Colson 1990; Cucchiara
1996, Varty 1993).
There are fourmain types of therapy in infants withGOR: surgery,
drugs, dietary measures (thickened feeds, frequent small meals)
and positioning (avoidance of slumped seated or supine postures).
Surgical treatment is usually reserved for complicated cases, while
most are treated with some combination of the other options.
Pharmacological therapies include acid-secretion inhibitors (e.g.
cimetidine, ranitidine, omeprazole, lansoprazole) with or without
prokinetic agents (e.g. cisapride, bethanechol, metoclopramide),
when oesophagitis is present.
Cisapride is administered orally 15-30 minutes before a meal to
ensure maximum plasma levels immediately after food intake. It
is a gastrointestinal prokinetic agent which stimulates lower oe-
sophageal, gastric, small intestinal and colonic motility, acting
probably by enhancing the release of acetylcholine at the level of
the myenteric plexus in the gut wall.
Although cisapride has never been licensed for children under 12
years it has been prescribed to over 36 million children world-
wide (Vandenplas 1999), including 19% of preterm newborns
in Canadian neonatal units (Ward 1999). In 1999, a consen-
sus statement by the European Society of Paediatric Gastroen-
terology, Hepatology and Nutrition (Vandenplas 1999) recom-
mended cisapride as the drug of first choice stating that “the
potential benefits far outweigh the potential risks and provide
strong justification for its continued use.” Since 1993 there have
been 175 reports worldwide of fatal cardiac arrhythmia or sud-
den death associated with cisapride use, at least two deaths in
children, and 261 non-fatal but serious ventricular arrhythmias
(Klausner 1998). These adverse events led to the withdrawal of
cisapride from the UK and USA markets in July 2000 (Henney
2000; Breckenridge 2000). To-date, the effectiveness of cisapride
for the treatment of reflux in children has not been systemati-
cally evaluated. As cisapride continues to be used, albeit within re-
stricted programmes in the USA (http://www.fda.gov/medwatch/
safety/2000/propul1.htm accessed 29.04.02) and Europe (http:
//www.emea.eu.int/pdfs/human/press/pr/392601en.pdf accessed
29.04.02) (Henney 2000), information on its effectiveness is re-
quired to enable clinicians and policy makers decide whether the
low risk of serious adverse events is outweighed by the benefits of
treatment.
O B J E C T I V E S
The objective of this review was to compare the effectiveness of
Cisapride in reducing the symptoms of gastro-oesophageal reflux
with:
1. placebo
2. other medical treatments
3. dietary interventions
4. positioning
5. any combination of other treatments
M E T H O D S
Criteria for considering studies for this review
Types of studies
Searches were carried out for randomised controlled trials compar-
ing oral cisapride therapy with placebo or with other non-surgical
treatments (other prokinetic drugs, with or without acid-secretion
inhibitors, dietary measures, positioning), in children with gastro-
oesophageal reflux. Searches for unpublished data are ongoing.
Types of participants
Children (less than18 years)with a diagnosis of gastro-oesophageal
reflux, however defined. We excluded trials in which the majority
of participants were aged less than 28 days. This is because cis-
apride is prescribed to neonates for feed intolerance. This is a dif-
ferent clinical entity from gastro-oesophageal reflux, may be due to
different physiological mechanisms, and may respond differently
to cisapride than does GORD in older children (Enriquez 1998).
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Types of interventions
1. Cisapride vs. placebo
2. Cisapride vs. other medical therapies (bethanechol, metoclo-
pramide, cimetidine, ranitidine, omeprazole, lansoprazole, Gavis-
con)
3. Cisapride vs. dietary interventions (small meals, thickened in-
fant feedings)
4.Cisapride vs. positioning (avoidance of slumped seated or supine
postures)
5. Cisapride vs. any combination of other non-surgical therapies
Because of the restriction of surgical treatment to complicated
cases of GOR we did not expect to find randomised controlled
trials in this area and they were not sought.
We looked for studies in which Cisapride was administered orally
for a minimum of one week.
Types of outcome measures
Cisapride treatment usually precedes physiological investigations
for GOR and primarily aims to improve symptoms and avoid
serious complications of GOR.
Primary outcomes:
* Symptoms, or change in symptoms, of gastro-oesophageal re-
flux (regurgitation, crying, irritability, vomiting, gagging) assessed
subjectively by the parent/guardian of child and/or by the treating
physician
* Presence of any of the following adverse events: abdominal pain,
borborygmi, diarrhoea, headaches, hypersensitivity, convulsions,
extrapyramidal effects, increased urinary frequency, liver function
abnormalities, increased QTc interval on ECG
* Occurrence of any clinical complications of GOR, e.g. respira-
tory symptoms
* Weight gain
Secondary outcomes:
* Episodes of reflux measured by extended oesophageal pH mon-
itoring: percentage of time during which pH<4 (“reflux index”),
number of episodes of pH<4, number of episodes of pH<4 lasting
>5 minutes, duration of longest episode of pH<4
* LES pressure measured by oesophageal manometry
* Histological evidence of oesophagitis on biopsy
Included studies had to report at least one of the primary outcomes.
Search methods for identification of studies
See: Collaborative Review Group search strategy
Searches were conducted of the Cochrane Central Trials Register
(CCTR) and the specialised trials register of the Cochrane Up-
per Gastrointestinal and Pancreatic Diseases Group (see Review
Group details for more information) using terms related to gastro-
oesophageal reflux and Cisapride.
In addition, the reviewers searched the MEDLINE and EM-
BASE electronic databases. The search strategy included appro-
priate MeSH terms and text terms including: cisapride, gastro-
oesophageal reflux, idiopathic gastro-oesophageal reflux, uncom-
plicated gastro-oesophageal reflux, gastro-oesophageal reflux dis-
ease, infantile reflux, regurgitation, excessive regurgitation, with
appropriate truncations and misspellings. These were combined
with the use of the most sensitive Cochrane trials filters. Reference
lists of relevant review articles and identified trials were scrutinised
and forward citation searches were performed in the Science Ci-
tation Index on all trials identified. The drug manufacturers were
contacted for any unpublished trials.
Searches were updated on 5 April 2002 using the above strat-
egy on pre-MEDLINE, EMBASE and the Cochrane Library. An
adapted strategy was used for Pub-Med. The pharmaceutical com-
pany Janssen was contacted for unpublished trials. The searches
were re-run in August 2003, May 2004, June 2005 and June 2006
and no new trials were found.
Data collection and analysis
Titles and abstracts of all studies identified by the electronic
searches were reviewed on screen independently by two reviewers
(CA, SM). All potentially eligible studies were retrieved in hard
copy and were independently reviewed by two researchers (CA,
SM) against the inclusion criteria. Disagreements were resolved
by consensus with provision for arbitration by a third reviewer if
required (RG or SL). Additional information was sought for one
included trial (Cohen 1999). The reasons for exclusion of trials
are given in the table of ’Characteristics of Excluded Studies’.
The methodological quality of the included trials was assessed in-
dependently by two reviewers (CA, SM) using a checklist devel-
oped for this purpose. For each included trial, information was
collected regarding the method of randomisation, allocation con-
cealment, blinding of outcome assessment, and the relevant in-
terventions and outcomes. Data were extracted independently by
two reviewers (CA, SM) and any discrepancies were discussed and
resolved. Data were then entered into the Review Manager soft-
ware by one reviewer (CA) and accuracy was checked by two other
reviewers (SM, RG).
We preferentially included symptoms assessed by parents as they
are likely to have greater contact with their child and therefore have
a more accurate view of the change in symptoms. However, where
parental assessments were not available, we included physician
measures of symptoms, as we considered that they were assessing
the same entity.
Studies reported symptoms or change in symptoms at the end of
the treatment period in a variety of ways. An a priori decision was
made to dichotomise data as ’same or worse’ vs ’improvement’ and
in a sensitivity analysis to examine the effect of redefining the out-
comes as ’any symptoms’ vs ’no symptoms’. Decisions about how
best to dichotomise the data were reached by two reviewers (RG,
SL) without knowledge of the results. Changes in oesophageal pH
measurements at the end of treatment were considered to be a sec-
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ondary outcome as pH measurements are not reliable (Hampton
1990) and correlate poorly with symptoms and response to treat-
ment (Cucchiara 1996). We were able to analyse results for the
reflux index (percentage of 24 h with oesophageal pH<4) as this
is the most common measure reported.
For dichotomous data, a random effects meta-analysis was per-
formed to determine a summary odds ratio. Where continuous
data outcomes were measured in a standard way across studies
(e.g. reflux index), the pooled weighted mean difference was cal-
culated, again using a random effects model. The denominators
for these calculations were all children for whom outcome data
had been reported. Analysis was by intention to treat. Sensitivity
analyses involved re-calculation of the summary OR for trials with
good allocation concealment. For the primary outcome of ’same or
worse’ symptoms, we analysed funnel plot asymmetry, and hence
the likelihood of bias, using the regression method as described by
Egger et al (Egger 1997). Evidence of heterogeneity was sought
using a standard chi square statistic.
Planned subgroup analyses in childrenunder andover one year old,
in those with uncomplicated and complicated gastro-oesophageal
reflux, those with neurological impairment, and in trials where
the assessment of outcomes was blinded vs those in which it was
non-blinded were not conducted as appropriate trials were not
identified.
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies; Characteristics of ongoing studies.
Nine trials met the inclusion criteria (see table of ’Characteris-
tics of Included Studies’). Eight of these compared the effects of
Cisapride with placebo (Cohen 1999; Cucchiara 1987; Escobar
Castro 1994; Levy 2001; Scott 1997; Van Eygen 1989(a)& Van
Eygen 1989(b); Vandenplas 1991). In two studies (Scott 1997;
Vandenplas 1991) positioning and/or thickened feeds were also
given in both experimental and control arms. One paper (Van
Eygen 1989(a) +b) presented data from three trials. Two of these,
on different patient populations, met our inclusion criteria; they
were used separately and are identified accordingly. In one trial
(Greally 1992) Cisapride was compared with Gaviscon with or
without Carobel. Preliminary results reported from an on-going
study of symptomatic children over 2 months old with biopsy-
proven oesophagitis were published in abstract form (Orenstein
2000, see “Characteristics of ongoing studies”). Unpublished data
are currently being sought.
Studies reported a change in symptoms following the interven-
tion, with some exceptions: the Escobar Castro 1994 study re-
ported symptoms at the end of the treatment period, and in the
study by Cucchiara 1987 improvement in symptoms alone could
not be separated from improvement in the pH probe results and
histopathological changes. Both these studies were included, how-
ever, and their contribution to the overall results was explored in
a sensitivity analysis.
The study by Levy 2001 only reported data on the QTc interval
of the ECG. These data were from a seven centre double blind,
placebo controlled study of 134 children on the safety and efficacy
of cisapride conducted from 1991-94 with the support of Janssen
Pharmaceutical Inc. Levy et al state that “because efficacy results
did not reach statistical significance (possibly because inclusion
criteria were too broadly defined), they were not published”. The
response to a request to Janssen-Cilag Ltd UK for unpublished
datawas that theywere not aware of any unpublished data. Further
information is being sought.
The children included in the trials were aged between 5 days and 5
years. They had a diagnosis of GOR defined by clinical symptoms
alone or with additional oesophageal pH monitoring. Children
were generally excluded from the trials if they required concomi-
tant therapy with drugs interfering with assessment of the study
drug, had reflux caused by known anatomic abnormalities, under-
lying disease, or infection of the GI tract or other organ system, or
had neurologic, metabolic, or renal disorders (see table of ’Char-
acteristics of Included Studies’).
The dosage used was 0.8 mg/kg/day, with three exceptions: in one
study (Cucchiara 1987) 0.9 mg/kg/day was used, in another (Van
Eygen 1989(a)) 0.45mg/kg/day, and in another study (Levy 2001)
0.6 mg/kg/day. The duration of the trials ranged between 2 and
8 weeks. In five of the eight trials included, Cisapride had been
supplied by the manufacturing company (Cohen 1999; Greally
1992; Scott 1997; Van Eygen 1989(a); Van Eygen 1989(b)).
Eight studies identified by the search strategy were excluded: in
two (Cucchiara 1990; Saye 1987) Cisapride had been given for
less than 24 hours; in three (Barnett 2001; Pezzati 2001; McClure
1999) Cisapride was administered to preterm infants with feed in-
tolerance; in two studiesCisapride was administered to preterm in-
fants prophylactically for feed intolerance (Enriquez 1998; Reddy
2000); and two studies did not report any of the outcomes re-
quired for inclusion in the review (Heine 1996; McClure 1999).
Risk of bias in included studies
Two trials reported adequate allocation concealment (Cohen
1999; Scott 1997). In the remaining seven the method for alloca-
tion concealment is unclear. In one study (Greally 1992) a double-
blind design was not feasible, due to the different mode of prepa-
ration and time of administration of Cisapride and Gaviscon with
or without Carobel. The remaining eight trials stated that they
were double blind but did not provide further details.
In only one case all of the infants randomized completed the study
(Greally 1992). Losses to follow up in the other studies varied
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from as little as one and three (Escobar Castro 1994; Cucchiara
1987) to as much as 30% of the randomized population in three
studies (Cohen 1999; Levy 2001; Vandenplas 1991). In the study
by Cucchiara 1987 the total number of patients included was re-
ported, as was the number of patients in each group who com-
pleted the trial, but not the number randomized to the treatment
and control arms. For this study, we made the assumption that
randomization had produced equal numbers in each group.
Effects of interventions
CISAPRIDE VS PLACEBO
Seven trials, including 236 participants, compared symptoms of
GOR after treatment with Cisapride or with placebo. Our analysis
of symptoms is based on parental evaluation in four trials (Cohen
1999; Escobar Castro 1994; Scott 1997; Vandenplas 1991) and
physician assessment in the remaining three trials. The pooled
odds ratio (random effects model) for Cisapride vs placebo for
’same or worse’ vs ’improvement’ was 0.34 (95%CI 0.10, 1.19).
The odds ratio after exclusion of the study by Escobar Castro
1994 (OR 0.59, 95%CI 0.22, 1.59) or the study by Cucchiara
1987 (OR 0.41, 95%CI 0.11, 1.54) did not change appreciably.
Analysis of the effects of Cisapride after redefining outcomes as
’any symptoms’ vs ’no symptoms’ was restricted to five trials (a
total of 156 participants) (Cucchiara 1987; Escobar Castro 1994;
Scott 1997; Van Eygen 1989(a); Van Eygen 1989(b); Vandenplas
1991). The pooled odds ratio (random effects) for Cisparide versus
placebo for ’any symptoms’ vs ’no symptoms’ was 0.19 (95%CI
0.08, 0.44).
The analysis of symptoms showed significant heterogeneity (chi
square = 24.23; df=6; p<0.0001for ’same or worse’ vs ’improve-
ment’; chi square = 3.69, df=4, p=0.0002 for ’any symptoms’ vs
’no symptoms’). The reasons for the heterogeneity are not obvious
from examination of the included trials which were conducted
in clinically similar populations and report similar baseline event
rates. The funnel plot was asymmetrical, suggesting an absence of
small studies showing small or no benefit of Cisapride. The inter-
cept with this method was -5.07 (95%CI: -7.18 to -2.95). This
result is consistent with publication bias favouring studies show-
ing a positive effect of cisapride. The results regarding the benefits
of cisapride should therefore be interpreted with caution.
Adverse events (principally diarrhoea) were reported in four trials
(a total of 190 participants). There were fewer adverse events in
the placebo than in the Cisapride group, but the difference was
not statistically significant (OR for Cisapride vs placebo 1.80,
95%CI 0.87-3.70). One trial (Levy 2001) reported data on the
QTc interval following 3-8 weeks of either cisapride or placebo.
No statistically significant differences were found between the two
groups in either total QTc interval duration or change in QTc
interval compared with baseline. Mean QTc was 408+/-21 ms
in the cisapride group and 399 +/- 21 ms in the placebo group,
and the change in QTc was 1.7 +/- 18 ms and 2.4 +/-20 ms,
respectively.
A primary outcome for our study was weight gain following the
intervention but none of the trials reported these data. For the
study by Cohen 1999, the mean difference in weight gain at the
end of the 2 week trial was based on data provided by the authors.
The difference between the two groups was not statistically signif-
icant (0.9 kg, 95%CI -0.38, 2.18).
Use of Cisapride was associated with a reduction in the reflux in-
dex, as measured by oesophageal pH monitoring in five studies.
The weighted mean difference for Cisapride vs placebo was -6.49
(95%CI -10.13, -2.85). Several other physiological measured were
reported. The difference between the Cisapride and the placebo
groups was not statistically significant for number of episodes of
pH<4 in 24 hours (data available from two studies), number of
reflux episodes lasting more than 5 minutes (data from three stud-
ies), or lower oesophageal sphincter pressure (data from two stud-
ies). The duration of the longest episode of reflux was significantly
reduced in the Cisapride group (data from 3 studies) (results not
shown).
For this review we also looked for histological evidence of oe-
sophagitis at biopsy. Three trials reported data. In Cohen 1999
only 6 of 68 patients underwent endoscopy and there was no dif-
ference in the presence of ’mild histologic oesophagitis’ between
the Cisapride and the placebo group (2/4 vs 1/2). In Cucchiara
1987 the degree of oesophagitiswas histologically defined as ’mild’,
’moderate’ or ’severe’ and transformed into a score. Cisapride was
more effective than placebo but only 3 of the 17 patients included
in the study had severe oesophagitis at the beginning. In Scott
1997 the biopsy was repeated at the end of the trial only if oe-
sophagitis had been present at baseline. The difference in abnor-
mal findings between the Cisapride and the placebo group (7/11
vs 5/9) was not statistically significant.
CISAPRIDE VS OTHER MEDICAL INTERVENTIONS
One study comparing Cisapride with Gaviscon (or Gaviscon and
Carobel in 21 of 24 cases) was identified (Greally 1992). The ’same
or worse symptoms’ were slightly more common in the cisapride
than in the gaviscon group but this difference was not significant:
odds ratio 3.26 (95%CI 0.93-11.38). The outcomes in this study
were based on evaluations by parents who were not blind to the
intervention.
D I S C U S S I O N
We found no clear evidence for a significant effect of cisapride
compared with placebo on symptoms of GOR in children. How-
ever, the midpoint estimate of the summary odds ratio was 0.34.
This result is likely to be an overestimate of the benefits of cis-
apride. The analysis of funnel plot asymmetry showed that the
intercept from the regression analysis was -5.07. In an analysis of
75 meta-analyses published in the Cochrane Library and in four
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leading journals, Egger 1997 reported intercepts varying from -
3.5 to + 3.5. In comparison, our result shows extreme asymme-
try reflecting an inverse association between study precision and
an apparent beneficial effect of cisapride. While this relationship
may reflect real differences between large and smaller trials, it may
be explained by publication bias favouring submission or publi-
cation of small positive studies rather than small negative studies.
This possibility is supported by the report of a multi-centre trial
of 134 children randomized to either cisapride or placebo (with or
without cimetidine) which were not published “because efficacy
results did not reach statistical significance (possibly because in-
clusion criteria were too broadly defined)” (Levy 2001). The four
smallest studies in this review had unclear allocation concealment,
which has been reported to be associated with an overestimate of
treatment effect (Schulz 1995). If the analysis was restricted to the
two trials with good allocation concealment, the summary odds
ratio was 1.94 (0.87, 4.31).
There was substantial heterogeneity of results between trials. The
source of this heterogeneity is unclear as there was no obvious
clinical heterogeneity (age, method of GOR diagnosis, dose and
length of interventions were broadly similar).
We found a statistically significant reduction in the reflux index
with Cisapride compared to placebo. The reflux index is generally
taken to be the percentage time pH<4 at 24 hour pH monitoring
and the reduction suggested by this analysis was equivalent to 1.5
hours (with 95%CI of 40 minutes to almost 2.5 hours). This
findinghowever has to be seen in the context of a lack of correlation
between the reflux index and clinical symptoms and the evidence
of publication bias.
Only one small study was found which compared the use of Cis-
apride with Gaviscon or a combination of Gaviscon and Carobel
and the results did not reach conventional levels of statistical sig-
nificance. No studies were identified comparing Cisapride with
other forms of treatment.
This review did not find a statistically significant difference in
adverse events between Cisapride and placebo. However, serious
adverse events are rare and are unlikely to be detected by small
trials. Recent reports from surveillance studies of death and life
threatening events potentially related to Cisapride, together with
the uncertain benefits of Cisapride, have led to the decision to stop
marketing Cisapride in the United States (Henney 2000).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Our findings of a lack of evidence for a beneficial effect of cisapride
contradict widely held opinions to the contrary (Vandenplas 1999;
Shulman 2000 ). This review found no statistically significant ef-
fect of cisapride on symptoms of GOR, although the results were
consistent with a substantial reduction, no effect, or even an in-
crease in symptoms associated with cisapride treatment compared
with placebo.Only one studywas foundwhich compared cisapride
with another treatment and its results do not show cisapride to
be more effective than Gaviscon with or without Carobel in the
treatment of GOR in children. In this review there was evidence
of substantial funnel plot asymmetry which may be explained by
publication bias. There was also statistical heterogeneity between
the trials which may be related to variation in study quality. For
these reasons, the results are uncertain and should be interpreted
with caution. Finally, this review has highlighted the paucity of
randomised controlled trial information for such a widely pre-
scribed drug. However, due to the potential for serious adverse
events, large randomised trials of Cisapride with long term follow-
up are unlikely to be conducted.
Implications for research
The literature search did not find sufficient trials to fulfil all the
objectives of this review. Due to the restricted use of Cisapride
since July 2000, a larger study to determine the effectiveness of
Cisapride for GOR in children is no longer possible.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Cohen 1999
Methods Randomized, double-blind, placebo-controlled trial
Participants Age < 36 mo
Clinical diagnosis of GOR: frequent V or R often associated with feeding difficulties and/or excessive
crying.
Baseline 24-h oesophageal pH monitoring: RI >=5% OR GOR score (Euler & Byrne) >=50.
Exclusion criteria: anatomic abnormality of the GI tract, previous GI surgery, treatment with anticholin-
ergics, theophylline, other diagnosis which could explain vomiting
Interventions 2 weeks of either:
Cisapride suspension (1mg/ml) 0.2 mg/kg qid (n=50*)
Placebo (n=45*)
Outcomes Parental evaluation at 2 weeks:
overall symptom intensity on VAS 0-10 cm (0=absence of symptoms, 10= could not be worse)
improvement (marked=complete or near complete resolution of symtoms, moderate=partial resolution,
minimal=slight improvement, unchanged, deterioration)
Evaluation during the 2 weeks of treatment:
presence of vomiting, gagging, crying (score 0-3).
AE: any, withdrawals due to AE.
Investigator assessessment at 2 weeks:
24-h oesophageal pH
oesophagitis at biopsy
Notes 68 patients (38, 30) completed the trial.
Withdrawn if: consent was withdrawn, serious AE, further investigations necessitated a change in treat-
ment.
A high proportion of patients had received prior treatment with: thickened feeds, positional therapy,
cisapride, H2 antagonists, antacids, metoclopramide, other
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
Cucchiara 1987
Methods Randomized, double-blind, placebo-controlled trial
Participants Age 75 days - 47 mo
Reflux oesophagitis in all (endoscopy and biopsy).
Diagnosis of GOR made by oesophageal pH (pH<4 for >=20”) and manometry.
10Cisapride treatment for gastro-oesophageal reflux in children (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Cucchiara 1987 (Continued)
Exclusion criteria: infections, neurologic, metabolic, renal disorders, abnormalities of the GI tract
Interventions 8 weeks of either:
Cisapride syrup (1mg/ml) 0.3 mg/kg tid
Placebo syrup
Outcomes Assessed at 8 weeks by investigator:
24-h pH
LES pressure
oesophagitis at biopsy
Improvement at end of treatment: cured (clinical, pH-metric and histological variables normalised),
improved (at least one of the three varaibles had improved), unchanged, worsened
Notes 3 patients were withdrawn: 2 febrile URTI, 1 failed to take drug continuously.
Other outcomes measured: peristalsis amplitude, clinical score
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
Escobar Castro 1994
Methods Randomized, double-blind, placebo-controlled study
Participants Age 3 mo - 5 yrs
V and R present.
GOR at oesophageal pH monitoring (RI <3.5% considered normal).
No organic pathology to justify the reflux.
Interventions 4 weeks of either:
Cisapride 0.2 mg/kg (n=15)
Placebo (n=15)
Outcomes Assessment at 2 and 4 weeks (probably by parents) of digestive symptoms: severe (R and/or V after each
meal of an important part of the meal), moderate (R of a small quantity more than once a day), mild (R
of a very small quantity once a day or sometime during the week), absent.
Investigator assessment at 4 weeks: 24-h oesophageal pH, AE, complications
Notes 1 drop-out in the cisapride group (’lack of motivation’).
Other outcomes measured: radiological image, endoscopy, respiratory symptoms improvement (nil, slight,
good, excellent)
Risk of bias
Item Authors’ judgement Description
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Escobar Castro 1994 (Continued)
Allocation concealment? Unclear B - Unclear
Greally 1992
Methods Randomized study.
Double-blind design was not feasible (see text for details)
Participants Age 2-18 mo
Chronic vomiting and GOR confirmed by 24h pH oesophageal monitoring (pH<4 for >=5% of the
recording period).
No neurological, respiratory, metabolic, GI disease, treatment with H2 antagonists, theophylline, anti-
cholinergic drugs
Interventions 4 weeks of either:
Cisapride p.o. 0.2 mg/kg qid (n=26)
Gaviscon 1/2 sachet to each 90 ml feed qid (n=24, 21 also had Carobel)
Outcomes Parental evaluation at 4 weeks of improvement (improved, not improved).
Investigator evaluation at 4 weeks of 24-h pH (RE was defined as pH<4 for >=15”)
Notes All 50 infants completed the study.
Other outcomes measured at 4 weeks: daily parental evaluation of severity of V: 0 (absent), 1(1-4 episodes/
day), 2 (>4 episodes/day), leading to a final symptoms score (range 0-1); improvement in diary scores
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
Levy 2001
Methods Randomized, double-blind, placebo-controlled study.
Participants Age 6 mo - 4 years (mean age 14.4 mo)
Min. 3 months of symptomatic GORwith failure to respond to at least 6 weeks of non-surgical treatment
other than cisapride
Interventions 3-8 weeks of either Cisapride 0.6 mg/kg/day or placebo.
Outcomes Data on QTc retained in 4 (68 patients) of 7 study centres (134 patients in total) in the trial. 19/68
excluded as ECGs recorded after 8 weeks of treatment. Mean QTc reported at 3-8 weeks of treatment
and mean difference in QTc from baseline
Notes Data on symptoms of GOR not published “because efficacy results did not reach statistical significance”
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Levy 2001 (Continued)
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
Scott 1997
Methods Randomized, double-blind, placebo-controlled trial
Participants Age 6 weeks - 2 years
Daily R or V during a 1 week baseline period
AND >=1 episode of GOR (pH<4 for >20”) at 18-h pH monitoring.
Exclusion criteria: not meeting the inclusion criteria, premature, previous GI surgery (excluding for ap-
pendicitis), illnesses & drugs that could interfere with cisapride, reflux due to known anatomic abnor-
malities, underlying disease, infection of the GI tract, parents who couldn’t express concern, comply with
study, complete diaries
Interventions 6 weeks of positioning and thickened feeds (where appropriate) and either:
Cisapride suspension (1mg/ml) 0.2 mg/kg qid (n=23)
Placebo suspension (n=26)
Outcomes Assessed at 2,4,6 weeks by parent and investigator: global evaluation of condition on VAS 0-100 mm (0=
the worst it’s ever been, 100=completely recovered); any AE, specific AE.
Assessed at 6 weeks by parent and investigator: global evaluation of overall treatment (deterioration=
symptoms worse, poor=no improvement, fair=slight improvement, persistence of some symptoms, good=
improvement, occasional symptoms, excellent=complete relief of symptoms).
Assessed at 6 weeks by investigator: 24-h pH, LES pressure, oesophagitis at biopsy
Notes 45 patients (21 Cisapride, 24 Placebo) were evaluable (4 were noncompliant or had violated protocol).
Other outcomes: various at 24-h pH, swallow pressure, daily diary recording of each episode (none, mild,
moderate, severe), score for R and V
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
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Van Eygen 1989(a)
Methods Three trials:
I open trial (n=69)
II (Van Eygen 1989a) randomized, double-blind, placebo-controlled trial (n=23)
III (Van Eygen 1989b) dose-response trial (n=50)
Participants Age 5 days - 12 mo
Excessive R or V at least twice a day in all children.
In trial II: GOR at radiology or pH monitoring in all children.
In trial III: GOR at radiology, endoscopy or pH monitoring in 16 children.
Non-pharmacologic measures (e.g. positioning, food thickening) had failed to improve the reflux
Interventions 4 weeks of either:
Trial II: Cisapride oral suspension 0.15 mg/kg tid (n=12)
Placebo oral suspension (n=11)
Trial III: Cisapride 0.1 mg/kg tid (n=14) (not used in the analysis)
Cisapride 0.2 mg/kg tid (n=14)
Placebo tid (n=17)
Outcomes Assessed at 2 and 4 weeks by the investigator: AE, global therapeutic result (poor=no change, fair=distinct
but slight improvement, good=marked reduction in R, excellent=virtually complete symptomatic cure)
Notes In trial III analysis based on 45 of 50 patients. There were 4 early drop-outs and 1 protocol violation and
a further 10 drop-outs (4 in the Cisapride 0.2 mg/kg group and 6 in the placebo group.
Other outcomes assessed at 2 and 4 weeks by investigator: severity of R (severe=the major part of the
meal is R, moderate=effortless R of a mouthful of feeding, slight=R of rather excessive saliva only, no R);
frequency of R (after each meal, at least twice a day, once a day or several times a week, never)
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
Van Eygen 1989(b)
Methods Trial III referred to above.
Participants
Interventions
Outcomes
Notes
Risk of bias
Item Authors’ judgement Description
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Van Eygen 1989(b) (Continued)
Allocation concealment? Unclear B - Unclear
Vandenplas 1991
Methods Randomized, double-blind, placebo-controlled trial
Participants Age 2 - 4 mo
Pathological GOR of V and R for > 2 weeks, >6 times/day AND abnormal oesophageal pH monitoring.
Exclusion criteria: reflux secondary to diseases (e.g. infections, allergy, pyloric stenosis)
Interventions 13-16 days of positional therapy and either:
Cisapride (1 mg/ml) 0.2 mg/kg qid (n=21)
Placebo (n=21)
Outcomes Parental evaluation of GOR severity at 2 weeks: 0 (no V at all), 1 (1-3 episodes of V or R/day), 2 (4-6
episodes of V or R/day), 3 (>6 episodes of V or R/day). NB: all had grade 3 at the beginning.
Investigator evaluation at 2 weeks: 24-h pH.
Notes None of the infants received milk-thickening products.
29 completed the study, 13 exclusions post-randomisation: unexpected weaning (3,3), withdrawal of
permission for second pH monitoring because symptoms had improved (4,1), lack of improvement &
parents refused to continue (0,2)
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
* Number of patients in brackets represents number randomized to respective treatment group.
AE=adverse events, GI=gastro-intestinal, GOR=gastro-oesophageal reflux, LES=lower oesophageal sphincter, R=regurgitation, RE=
reflux episode, RI=reflux index (percentage of time in 24 h during which pH<4), URTI=upper respiratory tract infection, V=vomiting,
VAS=visual analogue scale
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Barnett 2001 Study participants were preterm neonates.
Cucchiara 1990 Cisapride given i.v. in a single dose over 5 minutes. No mention of study being randomized
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(Continued)
Enriquez 1998 Cisapride was administered prophylactically during the introduction of enteral feeding by nasogastric tube to
preterm infants of less than 33 weeks gestation at birth
Heine 1996 The outcomes reported by this study (i.e. drooling) are not relevant to the review
McClure 1999 The outcomes reported in this study (i.e. half gastric emptying time, whole gastrointestinal transit time) are
not relevant to the review. Cisapride was prescribed for clinically diagnosed gastroesophageal reflux or poor feed
tolerance in very preterm infants (less than 32 weeks of gestation)
Pezzati 2001 Study participants were preterm neonates less than 34 weeks gestation. Cisapride was administered for feed
intolerance by naso-gastric tube
Reddy 2000 Preterm neonates less than 34 weeks gestation. Cisapride administered prophilactically during the introduction of
enteral feeding
Saye 1987 All infants and children were suspected of having GOR (and only 5 of them had digestive symptoms) and Cisapride
treatment was given for only 16 hours
Characteristics of ongoing studies [ordered by study ID]
Orenstein 2000
Trial name or title Cisapride, cimetidine, both, or neither for infantile esophagitis: symptomatic & histologic results
Methods
Participants 96 children > 2 months old with biopsy proven oesophagitis
Interventions 1. cisapride 0.2 mg/kg qid & placebo
2. cimetidine 10 mg/kg qid & placebo
3. cisapride + cimetidine
4. placebo + placebo
Outcomes Measured at 2, 6 and 12 months. Initial findings reported for 2 months.
1.symptoms measured by parents using the Infant Gastroesophageal Reflux Questionnaire
2. vomiting
3. crying
4. biospy measuring papillay height and basal layer thickness
Starting date December 1999
Contact information SR Orenstein, Academic Hospital of Pittsburgh, USA
Notes Cisapride vs no cisapride:
symptom questionnaire showed 86% with cisapride were well or better at 2 months compared with 70% for
no cisapride groups (if 3 lost to follow-up in cisapride groups and 8 given no cisapride were assumed to have
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Orenstein 2000 (Continued)
worse symptoms). No significant improvement in vomiting (frequency or volume)
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D A T A A N D A N A L Y S E S
Comparison 1. Main analysis for Cisapride vs placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 ’Worse, same or slight
improvement’ vs ’moderate or
excellent improvement’
7 236 Odds Ratio (M-H, Random, 95% CI) 0.34 [0.10, 1.19]
2 Reflux index 5 176 Mean Difference (IV, Random, 95% CI) -6.49 [-10.13, -2.85]
3 Adverse events 4 190 Odds Ratio (M-H, Random, 95% CI) 1.86 [0.88, 3.93]
Comparison 2. Main analysis for Cisapride vs Gaviscon/Carobel
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 ’Worse, same or slight
improvement’ vs ’moderate or
excellent improvement’
1 50 Odds Ratio (M-H, Random, 95% CI) 3.26 [0.93, 11.38]
Comparison 3. Sensitivity analyses for Cisapride vs placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Best case scenario 7 290 Odds Ratio (M-H, Random, 95% CI) 0.21 [0.08, 0.54]
2 Worst case scenario 7 290 Odds Ratio (M-H, Random, 95% CI) 0.70 [0.18, 2.65]
3 Change in outcome definition:
’any symptoms’ vs ’no
symptoms’ at end of treatment
4 139 Odds Ratio (M-H, Random, 95% CI) 0.19 [0.07, 0.51]
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Analysis 1.1. Comparison 1 Main analysis for Cisapride vs placebo, Outcome 1 ’Worse, same or slight
improvement’ vs ’moderate or excellent improvement’.
Review: Cisapride treatment for gastro-oesophageal reflux in children
Comparison: 1 Main analysis for Cisapride vs placebo
Outcome: 1 ’Worse, same or slight improvement’ vs ’moderate or excellent improvement’
Study or subgroup Treatment Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Vandenplas 1991 7/21 11/21 16.9 % 0.45 [ 0.13, 1.58 ]
Cohen 1999 27/38 15/30 18.0 % 2.45 [ 0.90, 6.68 ]
Van Eygen 1989(a) 2/12 3/11 13.2 % 0.53 [ 0.07, 4.01 ]
Van Eygen 1989(b) 2/10 7/11 13.4 % 0.14 [ 0.02, 1.03 ]
Escobar Castro 1994 1/14 14/15 9.7 % 0.01 [ 0.00, 0.10 ]
Scott 1997 10/20 7/16 16.5 % 1.29 [ 0.34, 4.82 ]
Cucchiara 1987 2/8 7/9 12.2 % 0.10 [ 0.01, 0.90 ]
Total (95% CI) 123 113 100.0 % 0.34 [ 0.10, 1.19 ]
Total events: 51 (Treatment), 64 (Control)
Heterogeneity: Tau2 = 1.97; Chi2 = 24.23, df = 6 (P = 0.00047); I2 =75%
Test for overall effect: Z = 1.69 (P = 0.092)
0.1 0.2 0.5 1 2 5 10
Favours treatment Favours control
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Analysis 1.2. Comparison 1 Main analysis for Cisapride vs placebo, Outcome 2 Reflux index.
Review: Cisapride treatment for gastro-oesophageal reflux in children
Comparison: 1 Main analysis for Cisapride vs placebo
Outcome: 2 Reflux index
Study or subgroup Treatment Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Vandenplas 1991 14 12.5 (8.61) 15 18.5 (11.62) 16.9 % -6.00 [ -13.41, 1.41 ]
Cohen 1999 38 7.1 (7.9) 30 10 (7.8) 35.3 % -2.90 [ -6.65, 0.85 ]
Escobar Castro 1994 14 3.83 (3.47) 15 13.42 (7.47) 32.3 % -9.59 [ -13.78, -5.40 ]
Scott 1997 18 15 (20) 15 20 (17) 7.2 % -5.00 [ -17.62, 7.62 ]
Cucchiara 1987 8 11.83 (11.07) 9 23.85 (13.57) 8.2 % -12.02 [ -23.74, -0.30 ]
Total (95% CI) 92 84 100.0 % -6.49 [ -10.13, -2.85 ]
Heterogeneity: Tau2 = 6.09; Chi2 = 6.46, df = 4 (P = 0.17); I2 =38%
Test for overall effect: Z = 3.49 (P = 0.00047)
-10 -5 0 5 10
Favours treatment Favours control
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Analysis 1.3. Comparison 1 Main analysis for Cisapride vs placebo, Outcome 3 Adverse events.
Review: Cisapride treatment for gastro-oesophageal reflux in children
Comparison: 1 Main analysis for Cisapride vs placebo
Outcome: 3 Adverse events
Study or subgroup Treatment Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Cohen 1999 42/50 32/45 56.7 % 2.13 [ 0.79, 5.76 ]
Escobar Castro 1994 0/14 0/15 Not estimable
Scott 1997 14/23 13/26 43.3 % 1.56 [ 0.50, 4.85 ]
Cucchiara 1987 0/8 0/9 Not estimable
Total (95% CI) 95 95 100.0 % 1.86 [ 0.88, 3.93 ]
Total events: 56 (Treatment), 45 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.17, df = 1 (P = 0.68); I2 =0.0%
Test for overall effect: Z = 1.63 (P = 0.10)
0.1 0.2 0.5 1 2 5 10
Favours treatment Favours control
Analysis 2.1. Comparison 2 Main analysis for Cisapride vs Gaviscon/Carobel, Outcome 1 ’Worse, same or
slight improvement’ vs ’moderate or excellent improvement’.
Review: Cisapride treatment for gastro-oesophageal reflux in children
Comparison: 2 Main analysis for Cisapride vs Gaviscon/Carobel
Outcome: 1 ’Worse, same or slight improvement’ vs ’moderate or excellent improvement’
Study or subgroup Treatment Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Greally 1992 12/26 5/24 100.0 % 3.26 [ 0.93, 11.38 ]
Total (95% CI) 26 24 100.0 % 3.26 [ 0.93, 11.38 ]
Total events: 12 (Treatment), 5 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.85 (P = 0.064)
0.1 0.2 0.5 1 2 5 10
Favours treatment Favours control
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Analysis 3.1. Comparison 3 Sensitivity analyses for Cisapride vs placebo, Outcome 1 Best case scenario.
Review: Cisapride treatment for gastro-oesophageal reflux in children
Comparison: 3 Sensitivity analyses for Cisapride vs placebo
Outcome: 1 Best case scenario
Study or subgroup Treatment Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Cohen 1999 27/50 30/45 20.8 % 0.59 [ 0.26, 1.35 ]
Cucchiara 1987 2/10 8/10 10.9 % 0.06 [ 0.01, 0.56 ]
Escobar Castro 1994 1/15 14/15 7.8 % 0.01 [ 0.00, 0.09 ]
Scott 1997 10/23 17/26 18.2 % 0.41 [ 0.13, 1.29 ]
Van Eygen 1989(a) 2/12 3/11 11.9 % 0.53 [ 0.07, 4.01 ]
Van Eygen 1989(b) 2/14 13/17 12.9 % 0.05 [ 0.01, 0.33 ]
Vandenplas 1991 7/21 11/21 17.5 % 0.45 [ 0.13, 1.58 ]
Total (95% CI) 145 145 100.0 % 0.21 [ 0.08, 0.54 ]
Total events: 51 (Treatment), 96 (Control)
Heterogeneity: Tau2 = 1.00; Chi2 = 16.80, df = 6 (P = 0.01); I2 =64%
Test for overall effect: Z = 3.20 (P = 0.0014)
0.1 0.2 0.5 1 2 5 10
Favours treatment Favours control
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Analysis 3.2. Comparison 3 Sensitivity analyses for Cisapride vs placebo, Outcome 2 Worst case scenario.
Review: Cisapride treatment for gastro-oesophageal reflux in children
Comparison: 3 Sensitivity analyses for Cisapride vs placebo
Outcome: 2 Worst case scenario
Study or subgroup Treatment Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Cohen 1999 39/50 15/45 16.6 % 7.09 [ 2.85, 17.65 ]
Cucchiara 1987 4/10 7/10 13.4 % 0.29 [ 0.04, 1.82 ]
Escobar Castro 1994 2/15 14/15 11.0 % 0.01 [ 0.00, 0.14 ]
Scott 1997 12/23 7/26 15.8 % 2.96 [ 0.90, 9.75 ]
Van Eygen 1989(a) 2/12 3/11 12.8 % 0.53 [ 0.07, 4.01 ]
Van Eygen 1989(b) 6/14 7/17 14.9 % 1.07 [ 0.26, 4.49 ]
Vandenplas 1991 7/21 11/21 15.6 % 0.45 [ 0.13, 1.58 ]
Total (95% CI) 145 145 100.0 % 0.70 [ 0.18, 2.65 ]
Total events: 72 (Treatment), 64 (Control)
Heterogeneity: Tau2 = 2.56; Chi2 = 35.41, df = 6 (P<0.00001); I2 =83%
Test for overall effect: Z = 0.53 (P = 0.60)
0.1 0.2 0.5 1 2 5 10
Favours treatment Favours control
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Analysis 3.3. Comparison 3 Sensitivity analyses for Cisapride vs placebo, Outcome 3 Change in outcome
definition: ’any symptoms’ vs ’no symptoms’ at end of treatment.
Review: Cisapride treatment for gastro-oesophageal reflux in children
Comparison: 3 Sensitivity analyses for Cisapride vs placebo
Outcome: 3 Change in outcome definition: ’any symptoms’ vs ’no symptoms’ at end of treatment
Study or subgroup Treatment Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Escobar Castro 1994 7/14 14/15 16.9 % 0.07 [ 0.01, 0.70 ]
Van Eygen 1989(a) 4/12 10/11 15.7 % 0.05 [ 0.00, 0.54 ]
Van Eygen 1989(b) 14/28 14/17 35.9 % 0.21 [ 0.05, 0.91 ]
Vandenplas 1991 16/21 18/21 31.4 % 0.53 [ 0.11, 2.59 ]
Total (95% CI) 75 64 100.0 % 0.19 [ 0.07, 0.51 ]
Total events: 41 (Treatment), 56 (Control)
Heterogeneity: Tau2 = 0.17; Chi2 = 3.58, df = 3 (P = 0.31); I2 =16%
Test for overall effect: Z = 3.28 (P = 0.0010)
0.1 0.2 0.5 1 2 5 10
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